FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362596870> ?p ?o ?g. }

• W4362596870 endingPage "3374" @default.
• W4362596870 startingPage "3374" @default.
• W4362596870 abstract "Abstract Introduction: There is a critical need to incorporate molecular assessments of minimal residual disease (MRD) during neoadjuvant immunotherapy, in order to identify individuals at high risk for disease recurrence based on analyses of circulating cell-free tumor DNA (ctDNA) landscapes. Here we employed longitudinal liquid biopsies to dynamically assess clinical outcomes with neoadjuvant immuno-chemoradiotherapy in patients with esophageal/gastroesophageal junction (E/GEJ) cancer. Methods: We utilized targeted error-correction sequencing to perform high-depth ctDNA next-generation sequencing for 141 serial plasma and 32 matched white blood cell (WBC) DNA samples from 32 patients with operable stage II/III E/GEJ cancer that received neoadjuvant immune checkpoint blockade (ICB) with chemoradiotherapy prior to surgery (NCT03044613). ctDNA analyses were performed at baseline, post-ICB induction, after completion of chemoradiotherapy (pre-op), and post-operatively (post-op). Using a tumor-agnostic WBC DNA-informed panel NGS approach we determined the cellular origin of plasma variants, filtering out germline and clonal hematopoiesis (CH) variants and evaluated ctDNA clonal dynamics over time. Molecular MRD was evaluated post-ICB, pre-op and post-op and correlated with recurrence-free (RFS) and overall survival (OS). Results: Twenty out of 32 patients had detectable ctDNA at any timepoint. Of the 12 patients with undetectable ctDNA, 9 had only CH- and/or germline-derived variants, while 3 patients had no detectable variants of any origin. ctDNA clearance post-ICB was correlated with tumor regression &gt;80% at the time of resection (Fischer’s exact p=0.04). The subset of patients that did not attain complete pathologic response was heterogeneous with respect to ctDNA dynamics; such that ctDNA clearance pre-op identified patients with longer OS despite residual tumor of &gt;0% at the time of resection (log rank p=0.06). Patients with undetectable ctDNA or ctDNA clearance pre-op had a longer RFS (log rank p=0.007) and OS (log rank p=0.03). Molecular MRD was associated with RFS and OS such that patients with ctDNA clearance post-op had longer RFS (log-rank p=0.007) and OS (log-rank p=0.017). Conclusion: ctDNA clearance post-ICB, pre-op and post-op reflects differential clinical outcomes for patients with E/GEJ cancer receiving neoadjuvant immuno-chemoradiotherapy. Understanding ctDNA dynamics and their relationship with pathological response and long-term outcomes can help identify patients at higher risk for recurrence and open a therapeutic window for future intervention. Citation Format: Blair V. Landon, Ronan J. Kelly, Ali H. Zaidi, Archana Balan, Jenna V. Canzoniero, Gavin Pereira, Zineb Belcaid, Russell K. Hales, K Ranh Voong, Richard J. Battafarano, Blair A. Jobe, Stephen C. Yang, Stephen Broderick, Jinny Ha, Kellie N. Smith, Elizabeth Thompson, Fyza Y. Shaikh, James R. White, Cynthia L. Sears, Eun J. Shin, Ali I. Amjad, Benny Weksler, Josephine L. Feliciano, Chen Hu, Vincent K. Lam, Valsamo Anagnostou. Circulating cell-free tumor DNA dynamics capture minimal residual disease with neoadjuvant immune checkpoint blockade plus chemoradiotherapy for patients with operable esophageal/gastroesophageal junction cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3374." @default.
• W4362596870 created "2023-04-06" @default.
• W4362596870 creator A5003313258 @default.
• W4362596870 creator A5011127454 @default.
• W4362596870 creator A5014036462 @default.
• W4362596870 creator A5019578689 @default.
• W4362596870 creator A5020149540 @default.
• W4362596870 creator A5021631207 @default.
• W4362596870 creator A5026052001 @default.
• W4362596870 creator A5026502766 @default.
• W4362596870 creator A5030962207 @default.
• W4362596870 creator A5034866567 @default.
• W4362596870 creator A5036141263 @default.
• W4362596870 creator A5036615948 @default.
• W4362596870 creator A5039431392 @default.
• W4362596870 creator A5048216930 @default.
• W4362596870 creator A5054587880 @default.
• W4362596870 creator A5054778894 @default.
• W4362596870 creator A5056510071 @default.
• W4362596870 creator A5059886787 @default.
• W4362596870 creator A5063752111 @default.
• W4362596870 creator A5072460569 @default.
• W4362596870 creator A5073509937 @default.
• W4362596870 creator A5075372434 @default.
• W4362596870 creator A5075885830 @default.
• W4362596870 creator A5082410046 @default.
• W4362596870 creator A5082613510 @default.
• W4362596870 creator A5086045945 @default.
• W4362596870 date "2023-04-04" @default.
• W4362596870 modified "2023-10-14" @default.
• W4362596870 title "Abstract 3374: Circulating cell-free tumor DNA dynamics capture minimal residual disease with neoadjuvant immune checkpoint blockade plus chemoradiotherapy for patients with operable esophageal/gastroesophageal junction cancer" @default.
• W4362596870 doi "https://doi.org/10.1158/1538-7445.am2023-3374" @default.
• W4362596870 hasPublicationYear "2023" @default.
• W4362596870 type Work @default.
• W4362596870 citedByCount "0" @default.
• W4362596870 crossrefType "journal-article" @default.
• W4362596870 hasAuthorship W4362596870A5003313258 @default.
• W4362596870 hasAuthorship W4362596870A5011127454 @default.
• W4362596870 hasAuthorship W4362596870A5014036462 @default.
• W4362596870 hasAuthorship W4362596870A5019578689 @default.
• W4362596870 hasAuthorship W4362596870A5020149540 @default.
• W4362596870 hasAuthorship W4362596870A5021631207 @default.
• W4362596870 hasAuthorship W4362596870A5026052001 @default.
• W4362596870 hasAuthorship W4362596870A5026502766 @default.
• W4362596870 hasAuthorship W4362596870A5030962207 @default.
• W4362596870 hasAuthorship W4362596870A5034866567 @default.
• W4362596870 hasAuthorship W4362596870A5036141263 @default.
• W4362596870 hasAuthorship W4362596870A5036615948 @default.
• W4362596870 hasAuthorship W4362596870A5039431392 @default.
• W4362596870 hasAuthorship W4362596870A5048216930 @default.
• W4362596870 hasAuthorship W4362596870A5054587880 @default.
• W4362596870 hasAuthorship W4362596870A5054778894 @default.
• W4362596870 hasAuthorship W4362596870A5056510071 @default.
• W4362596870 hasAuthorship W4362596870A5059886787 @default.
• W4362596870 hasAuthorship W4362596870A5063752111 @default.
• W4362596870 hasAuthorship W4362596870A5072460569 @default.
• W4362596870 hasAuthorship W4362596870A5073509937 @default.
• W4362596870 hasAuthorship W4362596870A5075372434 @default.
• W4362596870 hasAuthorship W4362596870A5075885830 @default.
• W4362596870 hasAuthorship W4362596870A5082410046 @default.
• W4362596870 hasAuthorship W4362596870A5082613510 @default.
• W4362596870 hasAuthorship W4362596870A5086045945 @default.
• W4362596870 hasConcept C121608353 @default.
• W4362596870 hasConcept C126322002 @default.
• W4362596870 hasConcept C143998085 @default.
• W4362596870 hasConcept C2777701055 @default.
• W4362596870 hasConcept C2778292576 @default.
• W4362596870 hasConcept C2778424827 @default.
• W4362596870 hasConcept C2778461978 @default.
• W4362596870 hasConcept C2779742542 @default.
• W4362596870 hasConcept C2779823535 @default.
• W4362596870 hasConcept C2780851360 @default.
• W4362596870 hasConcept C502942594 @default.
• W4362596870 hasConcept C530470458 @default.
• W4362596870 hasConcept C71924100 @default.
• W4362596870 hasConceptScore W4362596870C121608353 @default.
• W4362596870 hasConceptScore W4362596870C126322002 @default.
• W4362596870 hasConceptScore W4362596870C143998085 @default.
• W4362596870 hasConceptScore W4362596870C2777701055 @default.
• W4362596870 hasConceptScore W4362596870C2778292576 @default.
• W4362596870 hasConceptScore W4362596870C2778424827 @default.
• W4362596870 hasConceptScore W4362596870C2778461978 @default.
• W4362596870 hasConceptScore W4362596870C2779742542 @default.
• W4362596870 hasConceptScore W4362596870C2779823535 @default.
• W4362596870 hasConceptScore W4362596870C2780851360 @default.
• W4362596870 hasConceptScore W4362596870C502942594 @default.
• W4362596870 hasConceptScore W4362596870C530470458 @default.
• W4362596870 hasConceptScore W4362596870C71924100 @default.
• W4362596870 hasIssue "7_Supplement" @default.
• W4362596870 hasLocation W43625968701 @default.
• W4362596870 hasOpenAccess W4362596870 @default.
• W4362596870 hasPrimaryLocation W43625968701 @default.
• W4362596870 hasRelatedWork W2168952713 @default.
• W4362596870 hasRelatedWork W2249625608 @default.
• W4362596870 hasRelatedWork W2417835388 @default.
• W4362596870 hasRelatedWork W2572313545 @default.
• W4362596870 hasRelatedWork W2616626113 @default.
• W4362596870 hasRelatedWork W2901025411 @default.

• next